Aurinia Pharmaceuticals Inc
$ 15.85
1.21%
11 Jun - close price
- Market Cap 2,052,483,000 USD
- Current Price $ 15.85
- High / Low $ 16.00 / 15.47
- Stock P/E 7.39
- Book Value 4.34
- EPS 2.16
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.65 %
- 52 Week High 16.88
- 52 Week Low 7.29
About
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Analyst Target Price
$17.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-04 | 2025-07-31 | 2025-05-12 | 2025-02-27 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 0.25 | 1.53 | 0.23 | 0.16 | 0.16 | 0.01 | 0.1 | 0.01 | -0.07 | -0.19 | -0.09 | -0.08 |
| Estimated EPS | 0.16 | 0.22 | 0.16 | 0.15 | 0.1 | -0.016 | 0.02 | 0.01 | -0.14 | -0.16 | -0.17 | -0.19 |
| Surprise | 0.09 | 1.31 | 0.07 | 0.01 | 0.06 | 0.026 | 0.08 | 0 | 0.07 | -0.03 | 0.08 | 0.11 |
| Surprise Percentage | 56.25% | 595.4545% | 43.75% | 6.6667% | 60% | 162.5% | 400% | 0% | 50% | -18.75% | 47.0588% | 57.8947% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AUPH
2026-06-08 20:10:26
Aurinia Pharmaceuticals Inc. (AUPH) director Tina Susan Nova was granted 23,931 stock options as compensation, which are exercisable at $15.67 per share and will vest one year from the grant date of June 4, 2026. The options are set to expire on June 4, 2036. This transaction is classified as a grant/award acquisition, not a market purchase or sale of common shares.
2026-06-08 20:10:26
Aurinia Pharmaceuticals Inc. director Craig A. Johnson was granted 23,931 stock options as part of his compensation, with an exercise price of $15.67 per share. These options are set to vest one year from the grant date and will expire on June 4, 2036. The Form 4 filing indicates this was a grant, award, or other acquisition of derivative securities, and no open-market buying or selling was reported.
2026-06-08 20:10:26
Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey was granted 23,931 stock options with an exercise price of $15.67 per share. These options are part of his compensation, will vest one year from the grant date, and are set to expire on June 4, 2036. This transaction reflects a new award and not an open-market purchase or sale.
2026-06-08 20:10:26
Aurinia Pharmaceuticals director Kathleen Goetz was granted 23,931 Director Stock Options on June 4, 2026, as compensation. These options have an exercise price of $15.67 per share and will expire on June 4, 2036, vesting one year from the grant date. Following this award, her direct derivative holdings total 23,931 options.
2026-06-07 13:09:01
Aurinia Pharmaceuticals' (AUPH) CEO, Kevin Tang, indirectly purchased 814,606 common shares across several transactions between May 29, 2026, and June 2, 2026, totaling approximately $12.5 million. This significant acquisition, representing 6.66% of his total holdings, occurred just before positive news about the company's lead drug, Lupkynis, which showed a more than 50% reduction in the risk of kidney-related events or death in lupus nephritis patients. Lupkynis sales are increasing, and the company is already profitable, making this insider buy a potentially smart move for investors.
2026-06-07 12:09:01
Aurinia Pharmaceuticals' CEO, Kevin Tang, indirectly purchased 814,606 common shares for approximately $12.5 million between May 29 and June 2, 2026, through affiliated entities. This significant investment occurred shortly before the company reported positive long-term phase 3 trial results for its drug, Lupkynis, which showed a substantial reduction in kidney-related events for lupus nephritis patients. The article suggests that with rising profits and strong trial data, this CEO purchase signals a positive outlook for investors.
